ArticleFrontiers in medicine2022

Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib.

Daisuke Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.